Hostname: page-component-78c5997874-s2hrs Total loading time: 0 Render date: 2024-11-16T05:29:49.006Z Has data issue: false hasContentIssue false
  • English
  • Français

Neonatal and infant outcomes of clozapine exposure in pregnancy: A consecutive case series

Published online by Cambridge University Press:  13 August 2021

M.L. Imaz ,
S. Lera ,
B. Sureda ,
A. Roca ,
S. Andres ,
A. Giménez Palomo ,
E. Solé ,
A. Torres  and
L. Garcia-Esteve
M.L. Imaz*
Affiliation:
Unit Of Perinatal Mental Health, Department Of Psychiatry And Psychology, Idibaps, University Of Barcelona (ub), Hospital Clinic Barcelona, Barcelona, Spain
S. Lera
Affiliation:
Child And Adolescent Psychiatry And Psychology & Unit Of Perinatal Mental Health, Hospital Clinic Barcelona, Barcelona, Spain
B. Sureda
Affiliation:
Unit Of Perinatal Mental Health, Department Of Psychiatry And Psychology, Hospital Clinic Barcelona, Barcelona, Spain
A. Roca
Affiliation:
Unit Of Perinatal Mental Health, Department Of Psychiatry And Psychology, Hospital Clinic Barcelona, Barcelona, Spain
S. Andres
Affiliation:
Child And Adolescent Psychiatry And Psychology & Unit Of Perinatal Mental Health, Hospital Clinic Barcelona, Barcelona, Spain
A. Giménez Palomo
Affiliation:
Unit Of Perinatal Mental Health, Department Of Psychiatry And Psychology, Hospital Clinic Barcelona, Barcelona, Spain
E. Solé
Affiliation:
Unit Of Perinatal Mental Health, Department Of Psychiatry And Psychology, Hospital Clinic Barcelona, Barcelona, Spain
A. Torres
Affiliation:
Unit Of Perinatal Mental Health, Department Of Psychiatry And Psychology, Idibaps, Hospital Clinic Barcelona, Barcelona, Spain
L. Garcia-Esteve
Affiliation:
Unit Of Perinatal Mental Health, Department Of Psychiatry And Psychology, Idibaps, Hospital Clinic Barcelona, Barcelona, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Clozapine is a second-generation antipsychotic agent approved for treatment-resistant schizophrenia and risk reduction of recurrent suicidal behavior in schizophrenia and schizoaffective disorder. Given the known negative consequences of relapse of severe mental disorders for both mother and infant, the maintenance of clozapine during pregnancy is recommended.1 Studies of pregnancy regarding to clozapine have demonstrated a heterogenous range of neonatal and infant complications.2

Objectives

To evaluate neonatal and infants outcomes of clozapine exposure in pregnancy.

Methods

We report three cases of infants exposed to clozapine politherapy throughout pregnancy. The dose range for all women on clozapine was 200-600 mg/day. Infants were evaluated between 4-6 months of chronological age with the Bayley-III infant development scale (BSID-III)3 and with the Alarme Détresse Bébé Scale (ADBB)4 for the detection of early-signs of withdrawal.

Results

Women remained stable during pregnancy but presented obesity and gestational diabetes. Clozapine Newborn were born to term by caesarean section due to breech presentation (N=2) or instrumental delivery due to loss of fetal well-being (N=1). They presented normal weight (3500-3800 gr). Two presented Apgarmin1-5 9/10 and one Apgarmin1-5 6/8 which showed lethargy and low alertness during the first weeks of life. All showed normal capacity for sociability, reciprocity and development of language and communication. However, one baby had scores in the low normal zone for cognition and another for motor skills.

Conclusions

The infant’s risks of clozapine exposure during pregnancy should be discussed with women and weighed against those associated with other treatments and/or with untreated severe mental illness.

Keywords

clozapineneurodevelopmentNeonateInfant
Type
Abstract
Information
European Psychiatry , Volume 64 , Special Issue S1: Abstracts of the 29th European Congress of Psychiatry , April 2021 , pp. S479
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.